Q2 FY2026 EarningsQ2 FY2026 results beat consensus across key profitability metrics: net loss of -$38.3M was narrower than the -$41.9M expected, while Diluted EPS of -$0.63 beat the -$0.68 consensus. Operating expenses were lower than anticipated, primarily driven by disciplined R&D spending. Management reiterated a cash runway into 2028, supported by RMAT designation for miv-cel in naSPMS and an on-track rolling BLA submission for SPS in Q4 2026.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Kyverna Therapeutics(KYTX) the EBIT is -39.56 M (+10.93%), Beat estimate;the EPS is -0.63 (+35.05%), Beat estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
Revenue
TBA--
0.00B--
----
EBITExceed expectations
-0.04B10.93%
-0.04B1.67%
+0.00B9.26%
EPSExceed expectations
-0.6335.05%
-0.677930.11%
+0.04794.94%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf